We describe the methodology used for quantifying and characterizingporphyrinsinvarioustissuesand in excreta, in the diagnosisand monitoringof the therapeuticmodulationof biochemicaldisease activityin a 53-year-old white man who has a rare form of familialporphyriacutanea tarda with bone marrowratherthan hepaticexpressionof the disease. Liquidchromatographicand thin-layerchromatographicanalysesof the patients'surine and skin showed predominantlyheptacarboxylic porphyrin and uroporphyrin, whereas his stool and bile contained isocoproporphyrin and coproporphynn as the major products.The data reflectdefectiveuroporphynnogen decarboxylation. Bothanalyticalmethodsgave quantitatively similarresultsfor urinaryand fecal porphyrins. A triple-lumen perfusionstudy of samples procuredboth at the ampulla of Vater and 15 cm downstreamprovideddata for porphynns excreted in the bile and their reabsorption in the small intestine. We evaluated: (a) suppression by hypertransfusion of bone marrow overproduction of porphynns and (b) reductionof enteralabsorptionof porphyrinsby orallyadministered charcoal(Acta Char) and cholestyramine. Porphyria cutanea tarda (PCT), the moat common human porphyria, is characterized by diminished activity of uroporphyrinogen decarboxylase (EC 4.1.1.37), a cytosolic enzyme involved in heme biosynthesis (1).1 In familial PCT, an autosomal dominantly inherited disorder, the enzyme activity is reportedly about half of normal in the liver and erythrocytes (2-4), with a concomitant decrease in immunoreactive activity of the enzyme in erythrocytes (5-7). In the sporadic subtype of the disease, however, the catalytic (3,8) and immunoreactive enzyme activities (5, 6) in the erythrocytes are normal, despite deficient enzyme activity in the liver (2, 3, 8, 9 ). There are rarer forms of spontaneous uroporphyrmogen decarboxylase deficiency (10), one of which is expressed in a patient (G.B.) in whom results of erythrocyte studies in kindred are consistent with familial PCT (11). In this patient, erythrocyte uroporphyrinogen decarboxylase activity is less than 50% of control values (12), and two of his seven children exhibit similarly docreased enzymic activity but without porphyria. The expression of the metabolic defect in the bone marrow has been ascribed to a congenital dyserythropoietic anemia type I (11), in which the skin porphyrins derived from those which we obtained samples from the intestinal lumen at various locations in the proximal small bowel. Quantifying porphyrins in plasma, feces, and urine allowed for critical monitoring of the efficacy of hypertransfi.ision to suppress overproduction of porphyrin in the bone marrow and the ability of drugs such as charcoal and cholestyramine, which bind porphyrins in vitro, effectively to interrupt the enthral absorption of porphyrins.
Porphyria cutanea tarda (PCT), the moat common human porphyria, is characterized by diminished activity of uroporphyrinogen decarboxylase (EC 4.1.1.37), a cytosolic enzyme involved in heme biosynthesis (1) . 1 In familial PCT, an autosomal dominantly inherited disorder, the enzyme activity is reportedly about half of normal in the liver and erythrocytes (2) (3) (4) , with a concomitant decrease in immunoreactive activity of the enzyme in erythrocytes (5-7). In the sporadic subtype of the disease, however, the catalytic (3,8) and immunoreactive enzyme activities (5, 6) in the erythrocytes are normal, despite deficient enzyme activity in the liver (2, 3, 8, 9 ). There are rarer forms of spontaneous uroporphyrmogen decarboxylase deficiency (10), one of which is expressed in a patient (G.B.) in whom results of erythrocyte studies in kindred are consistent with familial PCT (11). In this patient, erythrocyte uroporphyrinogen decarboxylase activity is less than 50% of control values (12), and two of his seven children exhibit similarly docreased enzymic activity but without porphyria. The expression of the metabolic defect in the bone marrow has been ascribed to a congenital dyserythropoietic anemia type I (11), in which the skin porphyrins derived from those 
Materials and Methods

Procurement of Samples
Specimens of skin, colonic mucosa, plasma,bile, stool,and urine were procured from patient G.B., who was postulated to have bone-marrow expression of familial PCT. His photomutilation has included loss of fingers, earlobes, and lips (Figure 1) , caused by massive accumulation of porphyrins in the skin. The enterohepatic circulation of porphyrins was evaluated by a triple-lumen perfusion study. The details of this will be published elsewhere, but bile-stained intestinal perfusate at the ampulla of Vater and 15 cm downstream was procured by aspiration from proximal and distal ports. Porphyrin quantification (allowing for water flux) at these two sites demonstrated highly efficient enthral absorption of endogenous porphyrins (13) .
By monitoring plasma porphyrins in serum for a week, we evaluated the effects of treatment with porphyrin-binding drugs such as cholestyramine (4 g every 6 h) and charcoal (30 g every 3 h) as well as the effect of hypertransfusion with 14 pints of blood. We also quantified and characterized the concentrations of porphyrin in skin tissues, before and after therapy with charcoal.
Materials
A porphyrin ester marker kit containing eight-, seven-, six-, five-, and four-carboxylic porphyrins, and mesoporphyrin of the isomer I series was from Porphyrin Products, Logan, UT; TLC aluminum sheets pre-coated with silica gel 60 were from Wilshire Chemical Co., Gardena, CA; all other 
Extraction and Esterification of Porphyrins
Known volumes or weights of samples from patient G.B.
(1 to 3 mL of urine or plasma, 1 mL of bile, and 0.5 to 2.0 g of stool) were mixed with 20-fold greater volumes of methanol containing 50 mL of H2S04 per liter, and incubated overnight in the dark at room temperature.
After esterification of the porphyrins to their respective methyl esters, we centrifuged the mixture if necessary, combining the supernates of the same sample, and adjusting the pH to 8-10 with 100 mLIL NH4OH solution. We transferred the mixture to a separatory funnel and extracted the porphyrin esters several times with 10-mL aliquots of dichloromethane until extraction was complete, as judged by the absence of visible red porphyrin fluorescence under ultraviolet light. The extracts were dehydrated by ifitration through anhydrous sodium sulfate before the dichloromethane was removed by evaporation, in the dark, under air at room temperature. Biopsy specimens of colonic mucosa (13.4mg) and skin (5-50 mg) were homogenized separately with potassium phosphate buffer (50 mmoIJL, pH 7.0) in a VirTis homogenizer run at full speed for three 2-ruin intervals. Each sample was esterified and the porphyrins were extracted as described above.
Quantitative Estimation of Porphyrins
We analyzed each sample by both of the following methods.
HPLC. We redissolved the porphyrin methyl esters in 100 pL of dichloromethane, then injected 10-20 uL of this into a Waters Associates chromatograph (Model ALC/GPC 201) equipped with two Model 6000 A pumps and a normal-phase 30 x 0.39 cm p.Porasil column. We equilibrated the column with ethyl acetate/cyclohexane (40/60 by vol), which also was the mobile phase. The absorbance of the column effluent at 405 nm was recorded with a Waters Model 440 detector and the porphyrin methyl esters were identified by comparing their retention times with those of a standard mixture of porphyrin methyl esters. The porphyrins were quantified from their peak areas, with use of a Hewlett Packard 3390A Reporting Integrator.
TLC. The porphyrin methyl esters, in dichloromethane, were spotted onto the TLC plate and chromatographed with known porphyrin esters as markers. The solvent, CC14/CH2C12/ethyl acetate/ethyl propionate (2/2/1/1, by vol), was allowed to move to within 1 cm from the top edge of the plate. After drying the plate, we enhanced and stabilized the fluorescence of the separated porphyrin ester bands by immersing the plate in a second solvent containing dodecane/hexadecane/CHC13 (3/3/14, by vol) (15) . The fluorescent spots corresponding to the porphyrins were identified, then quantified with a Schoeffel SD 300 densitometer set at an excitation wavelength of 399 nm and an emission wavelength of 620 nm. Isocoproporphyrin was characterized according to its mobility on TLC plates, as reported by Day et al. (15) .
Results
Quantitative Analyses for Porphyrins in Urine, Stool,
Plasma, Bile, and Colonic Mucosa
Analysis for patient GB's urinary porphyrins by HPLC and TLC ( Figure 2 and Table 1) showed heptacarboxylic porphyrin to be the major component (49% of total), uroporphyrin (27%) the second most abundant. In stool, coproporphyrin (40%) and isocoproporphyrin (25%) were the major porphyrins (Figure 3) . Isocoproporphyrin, a distinct peak by TLC, was barely separated from coproporphyrin by HPLC. Both methods gave about the same values for total urinary and fecal porphyrins, i.e., approximately 10 mg/24 hand 250 g/g dry weight, respectively. Hexacarboxylic (30% of total), pentacarboxylic (23%), and heptacarboxylic (17%) porphyrins were the major components in the patient's plasma (Figure 4) . The porphyrin peaks were clearly separated in both methods. TLC analysin, however, revealed an additional single peak for isocoproporphyrin (10%) and a porphyrin peak co-migrating to about the same distance as the coproporphyrin marker. The latter probably represents a complex between coproporphyrin and an unknown molecule characterized as "Pu" by Day et al.
(15).
When we quantified plasma porphyrins, the values obtained by TLC were about 20% higher than those obtained by HPLC.
TLC analysis for porphyrin in bile ( Figure 5 ) gave distinctly superior results, although both TLC and HPLC revealed coproporphyrin as the major compound (approximately 49% of total) in bile. Copro-, isocopro-, and pentacarboxylic porphyrins were clearly separated by TLC.
HPLC analysis for prophyrins in biopsied colonic mucosa (13.4 mg fresh weight) showed clear separation of 2-to 8-carboxylic porphyrins ( Figure 6 and Table 1 ).
Effect of Oral Administration of Charcoal or Cholestyramine, and of Suppression of Bone Marrow, on Porphyrin Concentrations in Plasma
The data shown in Figure 7 indicate a dramatic and rapid decline in plasma porphyrins after administration of char- at these concentrations throughout the seven days of the study. Cholestyramine caused a decrease of about 60%, whereas with charcoal the decrease was to near normal by 15 h. Hypertransfusion with bone marrow suppression resulted in a 70 to 80% decrease in plasma porphyrin concentrations, more effective than cholestyramine, but the rate of decrease was in days rather than in hours.
Effectof Orally Ingested Charcoal on Skin Porphyrins
In Figure SA and B, we show elution profiles of skin porphyrins measured by HPLC method before and after therapy with charcoal. A punch skin-biopsy sample of 15mg fresh weight before therapy with charcoal sufficed for quantitative analysis for 2-to 8-carboxylic porphyrins, which were clearly resolved under our analytical conditions. Analysis of as little as 5 mg (wet weight) of skin showed clear separation of porphyrin peaks. Here, heptacarboxylic porphyrin (46%) and uroporphyrin (27%) were the major porphyrins. Thus, the pattern of porphyrins in the patient's skin and urine were very similar. Within two days after therapy with charcoal was begun, the patient's total skin porphyrin content had declined from about 1-5 g/g wet Chromatographicconditionsand identificationof peaks as tn Figs.2 and 3 weight to about 0.01-0.04 rg/g wet weight (Table 1) . Heptacarboxylic porphyrin and uroporphyrin in particular were decreased by the treatment.
This is an atypical case of congenital erythropoietic porphyria (11). The presence of fluorescent normoblasta, the absence of measurable porphyrins in the patient's (nonfluorescent) liver, and the defective erythrocyte uroporphyrinogun decarboxylase enzyme present in the prebend and in two of his seven children strongly suggest that his disease represents the expression of familial PCT by bone marrow instead of by the liver (11). His photomutilation, a classic feature of congenital erythropoietic porphyria, is accompa- is modified by bacterial enzymes in the intestine, which act on the vinyl groups to produce isocoproporphyrin
(19).
Plasma porphyrins, presumably derived from the bone marrow and from equilibration with the enterohepatic cycling of endogenous porphyrins, are in a rapid turnover pool.
The striking decrease in plasma porphyrin (Figure 7 ) after hypertransfusion to suppress bone marrow (20) confirms bone marrow expression of the metabolic lesion, but monitoring of the plasma porphyrins over a year has indicated that this suppression was effective for only about seven to 10 days (data not shown).
The triple-lumen perfusion study revealed the passage of more than 200 mg of porphyrin per day at the level of the ainpulla of Vater with a near 95% reabsorption of all (Figure 7) , suggesting rapid equilibration with the depleted portal venous porphyrin pool. The methodology also has allowed long-term surveillance of the biochemical efficacy of charcoal therapy (21) .
With regard to the skin, heptacarboxylic porphyrin (46%) followed by uroporphyrin (27%) were the major porphyrins-a proffle similar to that of urinary porphyrins. The high initial skin porphyrins (1-S g/g wet weight) were decreased to insignificant concentration (0.01-0.04 1uglg wet weight) by two days of oral therapy with charcoal, as documented by HPLC of a 15-mg punch-biopsy sample. Fig. 2 med by the urinary porphyrin excretion pattern typical of PCT (16), i.e., predominant excretion of heptacarboxylic porphyrin (49%) with large amounts of ureporphyrin (27%) and hexacarboxylic porphyrin (14%) . Isocoproporphyrin and coproporphryin constituted 65% of the total fecal porphyrin,
